文献速递胃肠动力与功能性疾病

临床试验:难治性肠易激综合征肠道导向催眠治疗应答预测因素的事后分析

Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-11-05

对448例难治性Rome III肠易激综合征患者进行二次分析,这些患者参与了一项证实6次与12次肠道导向催眠治疗非劣效的随机研究。基线非结肠症状评分较高的患者更易达到IBS症状严重程度量表评分下降≥50分,基线IBS症状严重程度量表较高且医院焦虑抑郁量表抑郁评分较低者更易达到腹痛改善≥30%。

要点

  • 76.3%的患者达到IBS症状严重程度量表评分下降≥50分,应答者基线非结肠症状评分较高(p=0.005)。
  • 59.8%的患者腹痛评分改善≥30%,其基线IBS症状严重程度量表较高(p=0.03)、医院焦虑抑郁量表抑郁评分较低(p=0.012)。
  • 54例(12%)退出肠道导向催眠治疗,退出者基线医院焦虑抑郁量表焦虑评分较高(p=0.034)。

核心结论

  • 数据提示胃肠道和肠外症状负担较高的患者最可能从针对难治性肠易激综合征的肠道特异性行为干预中获益。
  • 对胃肠道、躯体和心理症状特征的临床评估可能有助于选择接受肠道导向催眠治疗的患者。

研究设计与样本

  • 对448例难治性Rome III肠易激综合征患者的结局进行二次分析,这些患者参与了一项证实6次与12次肠道导向催眠治疗非劣效的随机研究。
  • 比较应答者与非应答者的基线特征,包括年龄、性别、肠易激综合征亚型、生活质量、IBS症状严重程度量表评分、非结肠症状评分和医院焦虑抑郁评分。
  • 应答定义为IBS症状严重程度量表评分下降≥50分或疼痛严重程度评分降低≥30%。

主要发现

  • 总体76.3%的患者达到IBS症状严重程度量表评分下降≥50分;应答者基线非结肠症状评分较高(p=0.005)。
  • 59.8%的患者达到腹痛评分改善≥30%,其基线IBS症状严重程度量表评分较高(p=0.03),基线医院焦虑抑郁量表抑郁评分较低(p=0.012)。
  • 54例患者(12%)退出肠道导向催眠治疗;与完成者相比,退出者基线医院焦虑抑郁量表焦虑评分较高(p=0.034)。

关键数值与推荐

  • 应答定义:IBS症状严重程度量表评分下降≥50分或疼痛严重程度评分降低≥30%。
  • 达到IBS症状严重程度量表评分下降≥50分的比例为76.3%。
  • 达到腹痛评分改善≥30%的比例为59.8%。
  • 退出肠道导向催眠治疗的比例为12%(54例)。

临床怎么用

  • 对胃肠道、躯体和心理症状特征的临床评估可能有助于选择接受肠道导向催眠治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gut-directed hypnotherapy is effective for patients with irritable bowel syndrome (IBS). Despite its considerable evidence base, gut-directed hypnotherapy is not widely available and remains a limited resource. This emphasises the need to select patients who are most likely to benefit. AIM: To determine whether baseline patient characteristics were predictive of response to gut-directed hypnotherapy in patients with IBS METHODS: We conducted a secondary analysis of outcomes of 448 patients with refractory Rome III IBS who participated in a randomised study confirming non-inferiority of 6 compared to 12 sessions of gut-directed hypnotherapy. We compared baseline patient characteristics, including age, sex, IBS subtype, quality of life and IBS-Symptom Severity Scale (IBS-SSS), non-colonic symptom score and Hospital Anxiety and Depression (HAD) score between responders and non-responders. We defined response as ≥50-point decrease in IBS-SSS or ≥30% reduction in pain severity scores. RESULTS: Overall, 76.3% achieved ≥50-point decrease in IBS-SSS. Responders had a higher baseline non-colonic symptom score (p = 0.005). Those who achieved ≥30% improvement in abdominal pain scores (59.8%) had higher baseline IBS-SSS (p = 0.03), and lower baseline HAD-depression score (p = 0.012). Fifty-four patients (12%) dropped out of gut-directed hypnotherapy. Compared to completers, dropouts had higher baseline HAD-anxiety score (p = 0.034). CONCLUSIONS: These data suggest that patients with a higher burden of gastrointestinal and extraintestinal symptoms are most likely to benefit from gut-specific behavioural intervention for refractory IBS. Clinical assessment of gastrointestinal, somatic and psychological symptom profiles may play a role in selecting patients for gut-directed hypnotherapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Devenney J, Hasan SS, Morris J, et al. Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis. Aliment Pharmacol Ther. 2023. PMID: 37927144. doi:10.1111/apt.17790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。